The induction of eosinophil peroxidase release: improved methods of measurement and stimulation

被引:37
作者
Adamko, DJ
Wu, YQ
Gleich, GJ
Lacy, P
Moqbel, R
机构
[1] Univ Alberta, Sch Med & Dent, Div Pediat Pulm Med, Dept Pediat,Pulm Res Grp, Edmonton, AB T6G 2S2, Canada
[2] Univ Utah, Dept Dermatol, Salt Lake City, UT USA
[3] Univ Alberta, Dept Med, Pulm Res Grp, Edmonton, AB, Canada
基金
加拿大健康研究院;
关键词
eosinophil; EPO; methodology; IgA;
D O I
10.1016/j.jim.2004.05.003
中图分类号
Q5 [生物化学];
学科分类号
071010 ; 081704 ;
摘要
The production. and release of eosinophil peroxidase (EPO) has. been associated with human pathology. Degranulation assays with eosinophils are typically very difficult to do, with very low release values. EPO is unique for its high cationic charge. As such, it adheres to most extracellular surfaces, rendering it more difficult to measure compared with other released cellular proteins. Based on the understanding of the sticky nature of EPO, we were concerned that EPO released in vitro cannot be reproducibly measured in the supernatants of stimulated cells. Instead, we suspected that much of the released EPO was left adherent to the tube walls. We chose to investigate the measurement of EPO activity using the peroxidase substrate, O-phenylenediamine (OPD). Unlike other peroxidase substrates, OPD is soluble in aqueous physiological solutions, which do not lyse cell membranes, thereby allowing us to add OPD directly to eosinophils and exclusively measure extracellular EPO. This novel approach would remove the concerns of incorrect EPO measurements due to its adhesive nature. In addition, we developed this method to quantify EPO release in terms of EPO concentration. Finally, using this technique, we have been able to demonstrate secretory IgA (s-IgA)-induced release of EPO. By using ORD, we have developed a more sensitive and specific method to analyze the release of extracellular EPO. (C) 2004 Elsevier B.V. All rights reserved.
引用
收藏
页码:101 / 108
页数:8
相关论文
共 15 条
[1]  
ABUGHAZALEH RI, 1989, J IMMUNOL, V142, P2393
[2]   The eosinophil as a therapeutic target in asthma: beginning of the end, or end of the beginning? [J].
Adamko, D ;
Odemuyiwa, SO ;
Moqbel, R .
CURRENT OPINION IN PHARMACOLOGY, 2003, 3 (03) :227-232
[3]  
ADAMKO D, 2002, CURR ALLERGY ASTHM R, P107
[4]   EOSINOPHILIC INFLAMMATION IN ASTHMA [J].
BOUSQUET, J ;
CHANEZ, P ;
LACOSTE, JY ;
BARNEON, G ;
GHAVANIAN, N ;
ENANDER, I ;
VENGE, P ;
AHLSTEDT, S ;
SIMONYLAFONTAINE, J ;
GODARD, P ;
MICHEL, FB .
NEW ENGLAND JOURNAL OF MEDICINE, 1990, 323 (15) :1033-1039
[5]   Evidence for local eosinophil differentiation within allergic nasal mucosa: Inhibition with soluble IL-5 receptor [J].
Cameron, L ;
Christodoulopoulos, P ;
Lavigne, F ;
Nakamura, Y ;
Eidelman, D ;
McEuen, A ;
Walls, A ;
Tavernier, J ;
Minshall, E ;
Moqbel, R ;
Hamid, Q .
JOURNAL OF IMMUNOLOGY, 2000, 164 (03) :1538-1545
[6]   Mechanisms of eosinophil-associated inflammation [J].
Gleich, GJ .
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2000, 105 (04) :651-663
[7]   Cytokines directly induce degranulation and superoxide production from human eosinophils [J].
Horie, S ;
Gleich, GJ ;
Kita, H .
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 1996, 98 (02) :371-381
[8]   Ligation of the β2 integrin triggers activation and degranulation of human eosinophils [J].
Kato, M ;
Abraham, RT ;
Okada, S ;
Kita, H .
AMERICAN JOURNAL OF RESPIRATORY CELL AND MOLECULAR BIOLOGY, 1998, 18 (05) :675-686
[9]   Regulatory mechanism of eosinophil peroxidase release from guinea pig eosinophils [J].
Kirino, Y ;
Mio, M ;
Kamei, C .
JAPANESE JOURNAL OF PHARMACOLOGY, 2000, 83 (04) :293-299
[10]   Intracellular localization of interleukin-6 in eosinophils from atopic asthmatics and effects of interferon γ [J].
Lacy, P ;
Levi-Schaffer, F ;
Mahmudi-Azer, S ;
Bablitz, B ;
Hagen, SC ;
Velazquez, J ;
Kay, AB ;
Moqbel, R .
BLOOD, 1998, 91 (07) :2508-2516